| Biomarker ID | 1651 |
| PMID | 30962764 |
| Year | 2019 |
| Biomarker | NLR (neutrophil to lymphocyte ratio) |
| Biomarker Basis | Ratio |
| Biomolecule | Others |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.62 (95% CI: 1.29-2.04) |
| Effect on Pathways | NA |
| Experiment | Progression Free Survival Vs No Progression Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | 32 studies were in included in this meta study. Including a total of 21949 patients. NLR information for Progression Free survival was available from 12 studies |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0 |
| Method Used | Immunological Test for leukocyte count |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |